Webinars

On this page you find information about past webinars hosted by the ACT Consortium.

Watch the recordings

1. Utility and performance of rapid diagnostic tests in areas with low malaria transmission (12 April 2016)
2. Cost-effectiveness of introducing rapid diagnostic tests for malaria in the private sector (6 April 2016)
3. Evaluating antimalarial safety (7 October 2014)

3. Evaluating antimalarial safety

View presentation slides

• Introduction and Overview of ACT Consortium research on safety: Professor David Schellenberg (London School of Hygiene & Tropical Medicine, UK) and Professor David Lalloo (Liverpool School of Tropical Medicine, UK)

• Can approaches for collecting participant-reported harms in malaria clinical drug trials be harmonised?Ms Elizabeth Allen (University of Cape Town, South Africa)

• A Centralized Safety Repository: Ms Cheryl Pace (Liverpool School of Tropical Medicine, UK)

• Facilitating harms data capture by non-clinicians utilizing a novel data collection tool: Ms Cheryl Pace (Liverpool School of Tropical Medicine, UK)

• Interactions between malaria and HIV drugs in malaria endemic areas – the InterACT trial: Dr Lasse Vestergaard (WHO Western Pacific Region, Philippines)

Background

Clinical trials are not suitable to identify rare, potentially serious adverse effects of drugs, or to define their safety in high risk populations.

Artemisinin-based combination therapies (or ACTs) are considered safe, but there are concerns over their potential to cause damage to parts of the brain. There is also a concern about their safety in patients infected with HIV.  

Collating safety data is a challenge in Africa, where most antimalarials are used and more vulnerable populations reside.

The Safety Data Collection Tools for Real-World Reporting developed by the ACT Consortium are the first step to providing more resources for researchers seeking user-friendly methods to evaluate antimalarial safety.